Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements

NCT05727176 is registered in ClinicalTrials.gov with Taiho Oncology, Inc. as lead sponsor.

NCT NCT05727176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05727176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements
Lead sponsor
Taiho Oncology, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
July 5, 2023
Completion date
December 31, 2026
Enrollment
120 (estimated)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cholangiocarcinoma, fgfr2 fusions, gene rearrangement